11 Einträge gefunden

1. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

   1. Gambacorti-Passerini, Carlo
   2. Cortes, Jorge E
   3. Lipton, Jeff H
   4. Kantarjian, Hagop M
   5. Kim, Dong-Wook
   6. Schafhausen, Philippe
   7. Crescenzo, Rocco

   2018 - Forschungsinformationssystem des UKE - frei zugänglich
2. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias

   1. Cortes, Jorge E
   2. Gambacorti-Passerini, Carlo
   3. Kim, Dong-Wook
   4. Kantarjian, Hagop M
   5. Lipton, Jeff H
   6. Lahoti, Amit
   7. Talpaz, Moshe

   2017 - Forschungsinformationssystem des UKE
3. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

   1. Cortes, Jorge E
   2. Khoury, Hanna J
   3. Kantarjian, Hagop M
   4. Lipton, Jeff H
   5. Kim, Dong-Wook
   6. Schafhausen, Philippe
   7. Matczak, Ewa

   2016 - Forschungsinformationssystem des UKE
4. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

   1. Brümmendorf, Tim H
   2. Cortes, Jorge E
   3. Khoury, Hanna J
   4. Kantarjian, Hagop M
   5. Kim, Dong-Wook
   6. Schafhausen, Philippe
   7. Conlan, Maureen G

   2016 - Forschungsinformationssystem des UKE
5. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

   1. Gambacorti-Passerini, Carlo
   2. Kantarjian, Hagop M
   3. Kim, Dong-Wook
   4. Khoury, Hanna J
   5. Turkina, Anna G
   6. Brümmendorf, Tim H
   7. Matczak, Ewa

   2015 - Forschungsinformationssystem des UKE
6. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

   1. Shah, Neil P
   2. Guilhot, François
   3. Cortes, Jorge E
   4. Schiffer, Charles A
   5. le Coutre, Philipp
   6. Brümmendorf, Tim H
   7. Kantarjian, Hagop M

   2014 - Forschungsinformationssystem des UKE
7. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

   1. Gambacorti-Passerini, Carlo
   2. Cortes, Jorge E
   3. Lipton, Jeff H
   4. Dmoszynska, Anna
   5. Wong, Raymond S
   6. Rossiev, Victor
   7. Pavlov, Dmitri

   2014 - Forschungsinformationssystem des UKE
8. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

   1. Gambacorti-Passerini, Carlo
   2. Brümmendorf, Tim H
   3. Kim, Dong-Wook
   4. Turkina, Anna G
   5. Masszi, Tamas
   6. Assouline, Sarit
   7. Durrant, Simon

   2014 - Forschungsinformationssystem des UKE
9. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

   1. Kantarjian, Hagop M
   2. Cortes, Jorge E
   3. Kim, Dong-Wook
   4. Khoury, H Jean
   5. Brümmendorf, Tim H
   6. Porkka, Kimmo
   7. Martinelli, Giovanni

   2014 - Forschungsinformationssystem des UKE
10. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

    1. Khoury, H Jean
    2. Cortes, Jorge E
    3. Kantarjian, Hagop M
    4. Gambacorti-Passerini, Carlo
    5. Baccarani, Michele
    6. Kim, Dong-Wook
    7. Zaritskey, Andrey

    2012 - Forschungsinformationssystem des UKE
11. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

    1. Cortes, Jorge E
    2. Kim, Dong-Wook
    3. Kantarjian, Hagop M
    4. Brümmendorf, Tim
    5. Dyagil, Irina
    6. Griskevicius, Laimonas
    7. Malhotra, Hemant

    2012 - Forschungsinformationssystem des UKE